New Antiretroviral Drug Safe and Effective for Patients Beginning HIV Treatment

by VR Sreeraman on  August 5, 2009 at 5:02 PM AIDS/HIV News
RSS Email Print This Page Comment
 New Antiretroviral Drug Safe and Effective for Patients Beginning HIV Treatment
Emory University researchers have found that a member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV.
Advertisement

They came to this conclusion after analysing the results of a two-year multisite phase III clinical trial, and comparing this drug with standard antiretroviral drugs.

Advertisement
"These results provide an additional potent, well tolerated treatment option for newly diagnosed patients with HIV infection," says lead author Dr. Jeffrey Lennox professor of medicine (infectious diseases) at Emory University School of Medicine.

A research article published in the journal The Lancet reveals that the scientists found that an HIV integrase inhibitor called Raltegravir is overall as effective as widely used efavirenz, a reverse transcriptase inhibitor.

The researchers also observed that Raltegravir had faster onset of action and fewer adverse side effects.

During the clinical trial, the researchers combined both with two other standard retroviral drugs, tenofovir and emtricitabine.

According to the report, 566 patients from 67 medical centers on five continents were involved in the trial.

The "primary endpoint" of the trial was pushing viral levels below 50 copies per ml of blood by week 48.

The research hers said that 86 percent of the participants in the raltegravir group reached that goal, compared with 82 percent of the efavirenz group.

They further said that half the raltegravir group reached the endpoint by week four, compared with less than 20 percent for the efavirenz group.

The researchers also found the raltegravir group to encounter fewer side effects, such as headache, dizziness, and elevation in levels of cholesterol.

The authors note that raltegravir is usually taken twice a day, which may be more difficult for some patients.

However, they add, raltegravir's reduction in side effects and concerns about the ability of efavirenz to cause birth defects may be advantages for raltegravir.

Source: ANI
LIN
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive